ClinicalTrials.gg
CompletedNCT04346654XPAG-ITPUpdated May 16, 2025Results posted

A Study to Assess Efficacy and Safety of Eltrombopag in Combination With a Short Course of Dexamethasone in Patients With Newly Diagnosed ITP

A Phase 2 interventional study of Eltrombopag and Dexamethasone in Immune Thrombocytopenia (ITP), sponsored by Novartis Pharmaceuticals. Completed at 10 sites in Germany. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2025-05-16.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
26
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic — 7 open to participants now, 7 under way, none of them phase 3. eltrombopag · Purpura, Thrombocytopenic, Idiopathic.

Enrollment
26th of 36
26 · median 40
Started
2020
with 2 others
Phase 2
15 of 36
2 open now
Registered
27th of 36
by date
Lead sponsor
6 of 36
Novartis Pharmaceuticals

Among the 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic, this one is the 26th largest by enrollment, is one of 3 that started in 2020, is one of 15 in phase 2, and was the 27th registered.

Purpura, Thrombocytopenic, Idiopathic

504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Open to participants now

7 of the 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic are open now, in 3 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About eltrombopag

eltrombopag: first FDA approval 2008 (PROMACTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic, or all of them as a file.
02

Study summary

The purpose of this study was to compare the ability of eltrombopag in combination with a short course of high-dose dexamethasone to induce sustained response off treatment in patients with newly-diagnosed ITP versus 1-3 cycles of dexamethasone monotherapy.

The unmet clinical need and the potential for eltrombopag when added to steroids to improve the treatment outcome and the potential to induce sustained response off treatment serve as the basis for clinical investigation of eltrombopag in first-line ITP.

Read the detailed description

This is a Phase II, multicenter, 1:1 randomized, open-label study that compared the efficacy and safety of eltrombopag in combination with a short course of high-dose dexamethasone to 1-3 cycles of high-dose dexamethasone monotherapy, as first-line treatment in adult patients with newly diagnosed ITP.

Adult patients with newly diagnosed ITP who had platelet counts \< 30 × 10\^9/L and required treatment were screened, and if eligible, were randomized to either Arm A (eltrombopag in combination with a short course of dexamethasone) or Arm B (1-3 cycles of dexamethasone monotherapy).

The study was conducted in the following periods:

Screening Period: Patients were screened for 14 days based on the inclusion and exclusion criteria.

Treatment Period: Arm A: Patients were treated for 26 weeks during the treatment period. Patients who reached platelet counts ≥ 30 × 10\^9/L and maintained counts ≥ 30 × 10\^9/L during the tapering phase were eligible for treatment discontinuation. Duration of tapering before treatment discontinuation at Week 26 was 6 weeks. Arm B: Patients were treated up to 12 weeks during the treatment period. Patients who reached platelet counts ≥ 30 × 10\^9/L and maintained counts ≥ 30 × 10\^9/L after 1-3 cycles of dexamethasone treatment were eligible for treatment discontinuation. Patients with platelet counts \< 30 × 10\^9/L after 3 cycles of dexamethasone treatment were offered a course of eltrombopag treatment within the study and were discontinued from study at week 52.

Observation period: After completion of the treatment period, all patients were observed for sustained response off treatment until week 52. Only patients with sustained response at week 52 were followed for another 26 weeks.

03

Conditions studied

  • Immune Thrombocytopenia (ITP)

Keywords

  • ITP
  • Eltrombopag
  • Dexamethasone
  • Sustained response off treatment
  • TFR
  • Adult
  • ETB115
  • Platelets
  • Thrombocytopenic
  • Thrombopoietin receptor Agonist
  • Newly-diagnosed
  • Blood bleeding disorder
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed must be obtained prior to participation in the study.
  • Men and women ≥ 18 years of age
  • Newly diagnosed with primary ITP (time from diagnosis within 3 months)
  • count \< 30 × 109/L at screening and a need for treatment (per physician's discretion) Note: If pre-treatment is necessary, platelet count data performed directly before pre-treatment (can be used for study inclusion (screening value). Treatment-naïve patients will be included based on their platelet counts performed at screening

Exclusion criteria

Exclusion Criteria:

  • Previous history of treatment for ITP, except any ITP-directed therapy for a maximum of 3 days within 7 days before randomization
  • Patients with diagnosis of secondary thrombocytopenia
  • Patients who have life threatening bleeding complications per physician´s discretion
  • Patients with a history of thromboembolic events in the 6 months preceding enrollment or known risk factors for thromboembolism
  • Serum creatinine > 1.5 mg/dL
  • Total (TBIL) > 1.5 × (ULN)
  • (AST) > 3.0 × ULN
  • Alanine transaminase (ALT) > 3.0 × ULN
  • Patients who are human immune deficiency virus (), virus (HCV) or surface antigen (HBsAg) positive
  • Patients with hepatic impairment ( score > 5)
  • Patients with known active or uncontrolled infections not responding to appropriate therapy
  • History of current diagnosis of cardiac disease or impaired cardiac function denoted
  • Patients who have active
  • Patients with evidence of current alcohol/drug abuse
  • Any serious and/or unstable pre-existing medical, psychiatric disorder, or other conditions that could interfere with subject's safety, obtaining or compliance with the study procedures
  • Female subjects who are nursing or pregnant (positive serum or urine B-human chorionic gonadotrophin (B-hCG) pregnancy test) at screening or pre-dose on Day 1
  • Women of and males unwilling to use adequate during the study
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    Eltrombopag + Dexamethasone

    Patients were treated with eltrombopag in combination with a standard high-dose dexamethasone (1 cycle: 40 mg once daily (QD) from day 1-4) to induce sustained response off treatment.

    Drug: Eltrombopag · Drug: Dexamethasone

  • Active comparator
    Dexamethasone

    Patients were treated with a standard high-dose dexamethasone (1-3 cycles: 40 mg QD day 1-4 at 4 weeks intervals (or at 14-28 days intervals if needed) to induce sustained response off treatment.

    Drug: Dexamethasone

Interventions

  • Eltrombopag is for oral use and comes in 25, 50 and 75 mg tablets. Prescribed dose is taken once daily.

    Also known as: ETB115

  • Dexamethasone is for oral use and comes in 8 mg tablets. Prescribed dose is taken once daily.

06

What researchers measure

Primary outcomes

  1. Percentage of Patients With Sustained Response Off Treatment at 52 Weeks

    Sustained response off treatment at 52 weeks is defined as maintenance of platelet count ≥ 30 × 10\^9/L after treatment discontinuation until Week 52 in the absence of bleeding events ≥ Grade II or use of any rescue medication at all visits until Week 52. Bleeding events ≥ Grade II are assessed by the modified World Health Organization (WHO) Bleeding Scale; Bleeding is graded based on a 1-4 scale (1=minor bleeding to 4=severe bleeding). Characteristics of bleeding events ≥ Grade II include: epistaxis ≥30 minutes, large purpura, joint bleeding, melanotic stool, hematemesis, gross hematuria, abnormal vaginal bleeding, hemoptysis, Visible blood in body cavity fluid, retinal bleeding, bleeding at invasive sites, bleeding requiring transfusion, bleeding associated with moderate or severe hemodynamic instability, fatal bleeding, CNS bleeding.

    Time frame: Study treatment discontinuation until week 52

Secondary outcomes

  1. Percentage of Patients With Overall Response at Week 52

    Overall response after treatment at week 52 was defined as maintenance of platelet count ≥ 30 x 109/L and ≥ 2-fold increase of screening platelet count after treatment discontinuation in the absence of bleeding event ≥ Grade II and no rescue therapy at all visits until Week 52. Bleeding events ≥ Grade II are assessed by the modified World Health Organization (WHO) Bleeding Scale; Bleeding is graded based on a 1-4 scale (1=minor bleeding to 4=severe bleeding). Characteristics of bleeding events ≥ Grade II include: epistaxis ≥30 minutes, large purpura, joint bleeding, melanotic stool, hematemesis, gross hematuria, abnormal vaginal bleeding, hemoptysis, Visible blood in body cavity fluid, retinal bleeding, bleeding at invasive sites, bleeding requiring transfusion, bleeding associated with moderate or severe hemodynamic instability, fatal bleeding, CNS bleeding.

    Time frame: Study treatment discontinuation until week 52

  2. Duration of Sustained Response Off Treatment

    Duration of sustained response off treatment is defined as time of treatment discontinuation until platelet count \< 30 × 109/L or bleeding events ≥ Grade II or use of any rescue therapy. If sustained response remains, the interval was censored with the date of the last platelet assessment. Bleeding events ≥ Grade II are assessed by the modified World Health Organization (WHO) Bleeding Scale; Bleeding is graded based on a 1-4 scale (1=minor bleeding to 4=severe bleeding). Characteristics of bleeding events ≥ Grade II include: epistaxis ≥30 minutes, large purpura, joint bleeding, melanotic stool, hematemesis, gross hematuria, abnormal vaginal bleeding, hemoptysis, Visible blood in body cavity fluid, retinal bleeding, bleeding at invasive sites, bleeding requiring transfusion, bleeding associated with moderate or severe hemodynamic instability, fatal bleeding, CNS bleeding.

    Time frame: from last dose of study treatment until loss of response, approx. 52 weeks

  3. Overall Response by Week 4

    Overall response by week 4 is defined as platelet count ≥ 30 × 109/L and ≥ 2 fold increase of screening platelet count and absence of bleeding and no rescue therapy within the first 4 weeks

    Time frame: By Week 4

  4. Complete Response by Week 4

    Complete Response by week 4 is defined as platelet count ≥ 100 × 109/L and absence of bleeding and no rescue therapy until week 4.

    Time frame: By Week 4

  5. Absolute Change in Platelet Count From Pre-treatment/Screening to Baseline and to Various Time Points

    Absolute change in platelet count from pre-treatment or screening to baseline (week 1) and from pre-treatment / screening to 2, 4, 13, 27 and 53 weeks. If pre-treatment was necessary before inclusion, platelet count data performed directly before pre-treatment were used for study inclusion (screening value to be used for inclusion/exclusion check and for analysis as a covariate).

    Time frame: Pre-treatment/screening, Week 1 (baseline), 2, 4, 13, 27, and 53

  6. Relative Change in Platelet Count From Pre-treatment/Screening to Baseline and to Various Time Points

    Relative change in platelet count from pre-treatment or screening to baseline (week 1) and from pre-treatment or screening to 2, 4, 13, 27, and 53 weeks. If pre-treatment was necessary before inclusion, platelet count data performed directly before pre-treatment were used for study inclusion (screening value to be used for inclusion/exclusion check and for analysis as a covariate).

    Time frame: Pre-treatment/screening, Week 1 (baseline), 2, 4, 13, 27, and 53

  7. Time to Overall Response (TOR)

    Time to overall response is defined as time from starting study treatment to time of achievement of overall response. Overall response is defined as a platelet count ≥ 30 × 10\^9/L and ≥ 2 fold increase of baseline platelet count and absence of bleeding and no rescue therapy censored with the last visit date for patients not achieving overall response. Results of TOR are reported per Kaplan-Meier estimates.

    Time frame: Time from starting study treatment to achievement of complete response (up to 52 weeks)

  8. Time to Complete Response

    Time to complete response is defined as time from starting study treatment to time of achievement of complete response. Complete response is defined as a platelet count ≥ 100 × 109/L and absence of bleeding and no rescue therapy. Results of time to complete response are reported per Kaplan-Meier estimates.

    Time frame: Time from starting study treatment to achievement of complete response (up to 52 weeks)

  9. Duration of Overall Response (OR) and Complete Response (CR)

    Duration of overall or complete response (CR) is defined as time of achievement of overall or CR until loss of overall or CR. The duration of CR was calculated from the date of onset of CR until platelet count \< 100 x 109/L, or bleeding events ≥ Grade II (assessed by the modified World Health Organization (WHO) Bleeding Scale) or use of any rescue therapy, whatever was earlier. Bleeding is graded based on a 1-4 scale (1=minor bleeding to 4=severe bleeding). Characteristics of bleeding events ≥ Grade II include: epistaxis ≥30 minutes, large purpura, joint bleeding, melanotic stool, hematemesis, gross hematuria, abnormal vaginal bleeding, hemoptysis, Visible blood in body cavity fluid, retinal bleeding, bleeding at invasive sites, bleeding requiring transfusion, bleeding associated with moderate or severe hemodynamic instability, fatal bleeding, CNS bleeding. Results of duration of overall and complete response are reported per Kaplan-Meier estimates.

    Time frame: Achievement of overall or complete response until loss of response (up to 52 weeks)

  10. Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Questionnaire

    The Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) instrument is a 13-item validated tool used to measure an individual's level of fatigue during usual daily activities over the past 7 days. Items are scored on a 0-4 response scale (4=not at all to 0=very much) where the total possible score ranges from 0-52 (all items are summed up to create the total score); A score of less than 30 indicates severe fatigue. The higher scores represent better HRQoL.

    Time frame: Baseline (Week 1), Week 2, 3, 5, 13, 27 and 53

  11. Change From Baseline in Short Form 36 Health Survey (SF-36v2) Questionnaire (Physical (PS), Mental Score (MS) and Alternative Scoring (PS-QM))

    SF36 questionnaire is a tool to measure health-related QoL. SF36 questionnaires (physical and mental score) were answered throughout the study and is a validated instrument with 36 questions to measure general physical and mental health status via assessment of 8 domains-Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role Emotional, and Mental Health-over the past 4 weeks. The SF36 is scored using norm-based scoring procedures and scores ranging from 0-100; higher values indicate less impairment, a higher QoL. In addition to this SAP-planned scoring score, an alternative scoring for both the physical SF36 score and the mental SF36 were performed by QualityMetric (QM) Incorporated, an IQVIA business.

    Time frame: Baseline (Week 1), Week 2, 3, 5, 13, 27 and 53

  12. Incidence and Severity of Bleeding Events

    Incidence and severity of bleeding assessed by the modified World Health Organization (WHO) Bleeding Scale; Bleeding is graded based on a 1-4 scale (1=minor bleeding to 4=severe bleeding). Incidence of bleeding: participants had at least one bleeding event. Severity of bleeding: bleeding event is from grade 2 and higher

    Time frame: Baseline up to 52 weeks

07

Results

Posted Mar 17, 2025

Participant flow

The study was conducted in 25 centers in Germany.

Participant flow — Overall Study
MilestoneEltrombopag + DexamethasoneDexamethasone
Started1313
Randomized, not treated10
Completed810
Not completed53
Withdrew: Adverse event20
Withdrew: Non-response11
Withdrew: Withdrawal by subject20
Withdrew: Lost to follow-up01
Withdrew: Pregnancy01

Outcome measures

PrimaryPercentage of Patients With Sustained Response Off Treatment at 52 Weeks

Sustained response off treatment at 52 weeks is defined as maintenance of platelet count ≥ 30 × 10\^9/L after treatment discontinuation until Week 52 in the absence of bleeding events ≥ Grade II or use of any rescue medication at all visits until Week 52. Bleeding events ≥ Grade II are assessed by the modified World Health Organization (WHO) Bleeding Scale; Bleeding is graded based on a 1-4 scale (1=minor bleeding to 4=severe bleeding). Characteristics of bleeding events ≥ Grade II include: epistaxis ≥30 minutes, large purpura, joint bleeding, melanotic stool, hematemesis, gross hematuria, abnormal vaginal bleeding, hemoptysis, Visible blood in body cavity fluid, retinal bleeding, bleeding at invasive sites, bleeding requiring transfusion, bleeding associated with moderate or severe hemodynamic instability, fatal bleeding, CNS bleeding.

Time frame:
Study treatment discontinuation until week 52
Reported as:
Count of participants · Participants
Percentage of Patients With Sustained Response Off Treatment at 52 Weeks
ParticipantsEltrombopag + DexamethasoneDexamethasone
Percentage of Patients With Sustained Response Off Treatment at 52 Weeks22
Statistical analysis
  • Eltrombopag + Dexamethasone vs Dexamethasone · Regression, Logistic · p = 0.5133
SecondaryPercentage of Patients With Overall Response at Week 52

Overall response after treatment at week 52 was defined as maintenance of platelet count ≥ 30 x 109/L and ≥ 2-fold increase of screening platelet count after treatment discontinuation in the absence of bleeding event ≥ Grade II and no rescue therapy at all visits until Week 52. Bleeding events ≥ Grade II are assessed by the modified World Health Organization (WHO) Bleeding Scale; Bleeding is graded based on a 1-4 scale (1=minor bleeding to 4=severe bleeding). Characteristics of bleeding events ≥ Grade II include: epistaxis ≥30 minutes, large purpura, joint bleeding, melanotic stool, hematemesis, gross hematuria, abnormal vaginal bleeding, hemoptysis, Visible blood in body cavity fluid, retinal bleeding, bleeding at invasive sites, bleeding requiring transfusion, bleeding associated with moderate or severe hemodynamic instability, fatal bleeding, CNS bleeding.

Time frame:
Study treatment discontinuation until week 52
Reported as:
Count of participants · Participants
Percentage of Patients With Overall Response at Week 52
ParticipantsEltrombopag + DexamethasoneDexamethasone
Percentage of Patients With Overall Response at Week 5222
Statistical analysis
  • Eltrombopag + Dexamethasone vs Dexamethasone · Regression, Logistic · p = 0.5133
SecondaryDuration of Sustained Response Off Treatment

Duration of sustained response off treatment is defined as time of treatment discontinuation until platelet count \< 30 × 109/L or bleeding events ≥ Grade II or use of any rescue therapy. If sustained response remains, the interval was censored with the date of the last platelet assessment. Bleeding events ≥ Grade II are assessed by the modified World Health Organization (WHO) Bleeding Scale; Bleeding is graded based on a 1-4 scale (1=minor bleeding to 4=severe bleeding). Characteristics of bleeding events ≥ Grade II include: epistaxis ≥30 minutes, large purpura, joint bleeding, melanotic stool, hematemesis, gross hematuria, abnormal vaginal bleeding, hemoptysis, Visible blood in body cavity fluid, retinal bleeding, bleeding at invasive sites, bleeding requiring transfusion, bleeding associated with moderate or severe hemodynamic instability, fatal bleeding, CNS bleeding.

Time frame:
from last dose of study treatment until loss of response, approx. 52 weeks
Reported as:
Mean · Weeks
Duration of Sustained Response Off Treatment
WeeksEltrombopag + DexamethasoneDexamethasone
Duration of Sustained Response Off Treatment49.1 ± 0.045.7 ± 2.8
SecondaryOverall Response by Week 4

Overall response by week 4 is defined as platelet count ≥ 30 × 109/L and ≥ 2 fold increase of screening platelet count and absence of bleeding and no rescue therapy within the first 4 weeks

Time frame:
By Week 4
Reported as:
Count of participants · Participants
Overall Response by Week 4
ParticipantsEltrombopag + DexamethasoneDexamethasone
Overall Response by Week 41011
SecondaryComplete Response by Week 4

Complete Response by week 4 is defined as platelet count ≥ 100 × 109/L and absence of bleeding and no rescue therapy until week 4.

Time frame:
By Week 4
Reported as:
Count of participants · Participants
Complete Response by Week 4
ParticipantsEltrombopag + DexamethasoneDexamethasone
Complete Response by Week 489
SecondaryAbsolute Change in Platelet Count From Pre-treatment/Screening to Baseline and to Various Time Points

Absolute change in platelet count from pre-treatment or screening to baseline (week 1) and from pre-treatment / screening to 2, 4, 13, 27 and 53 weeks. If pre-treatment was necessary before inclusion, platelet count data performed directly before pre-treatment were used for study inclusion (screening value to be used for inclusion/exclusion check and for analysis as a covariate).

Time frame:
Pre-treatment/screening, Week 1 (baseline), 2, 4, 13, 27, and 53
Reported as:
Mean · G/L
Absolute Change in Platelet Count From Pre-treatment/Screening to Baseline and to Various Time Points
G/LEltrombopag + DexamethasoneDexamethasone
Week 132.0 ± 44.323.2 ± 48.0
Week 2145.2 ± 151.980.7 ± 68.8
Week 4192.5 ± 165.892.0 ± 68.7
Week 13119.4 ± 115.9143.0 ± 88.5
Week 27217.8 ± 126.5141.2 ± 94.7
Week 53139.0 ± 88.0141.7 ± 61.4
SecondaryRelative Change in Platelet Count From Pre-treatment/Screening to Baseline and to Various Time Points

Relative change in platelet count from pre-treatment or screening to baseline (week 1) and from pre-treatment or screening to 2, 4, 13, 27, and 53 weeks. If pre-treatment was necessary before inclusion, platelet count data performed directly before pre-treatment were used for study inclusion (screening value to be used for inclusion/exclusion check and for analysis as a covariate).

Time frame:
Pre-treatment/screening, Week 1 (baseline), 2, 4, 13, 27, and 53
Reported as:
Mean · Percentage change in platelet counts
Relative Change in Platelet Count From Pre-treatment/Screening to Baseline and to Various Time Points
Percentage change in platelet countsEltrombopag + DexamethasoneDexamethasone
Week 1347.9 ± 486.8293.4 ± 418.4
Week 25795.5 ± 9672.42028.2 ± 4382.0
Week 411400.9 ± 16875.22865.4 ± 3805.4
Week 138050.6 ± 12277.84725.7 ± 8418.2
Week 2713667.9 ± 15717.14381.1 ± 8195.2
Week 539392.3 ± 11476.05612.1 ± 8300.7
SecondaryTime to Overall Response (TOR)

Time to overall response is defined as time from starting study treatment to time of achievement of overall response. Overall response is defined as a platelet count ≥ 30 × 10\^9/L and ≥ 2 fold increase of baseline platelet count and absence of bleeding and no rescue therapy censored with the last visit date for patients not achieving overall response. Results of TOR are reported per Kaplan-Meier estimates.

Time frame:
Time from starting study treatment to achievement of complete response (up to 52 weeks)
Reported as:
Median · Weeks
Time to Overall Response (TOR)
WeeksEltrombopag + DexamethasoneDexamethasone
Time to Overall Response (TOR)1.1 (0.0 to 4.1)1.0 (0.1 to 1.3)
SecondaryTime to Complete Response

Time to complete response is defined as time from starting study treatment to time of achievement of complete response. Complete response is defined as a platelet count ≥ 100 × 109/L and absence of bleeding and no rescue therapy. Results of time to complete response are reported per Kaplan-Meier estimates.

Time frame:
Time from starting study treatment to achievement of complete response (up to 52 weeks)
Reported as:
Median · Weeks
Time to Complete Response
WeeksEltrombopag + DexamethasoneDexamethasone
Time to Complete Response1.1 (0.1 to NA)2.1 (0.6 to NA)
SecondaryDuration of Overall Response (OR) and Complete Response (CR)

Duration of overall or complete response (CR) is defined as time of achievement of overall or CR until loss of overall or CR. The duration of CR was calculated from the date of onset of CR until platelet count \< 100 x 109/L, or bleeding events ≥ Grade II (assessed by the modified World Health Organization (WHO) Bleeding Scale) or use of any rescue therapy, whatever was earlier. Bleeding is graded based on a 1-4 scale (1=minor bleeding to 4=severe bleeding). Characteristics of bleeding events ≥ Grade II include: epistaxis ≥30 minutes, large purpura, joint bleeding, melanotic stool, hematemesis, gross hematuria, abnormal vaginal bleeding, hemoptysis, Visible blood in body cavity fluid, retinal bleeding, bleeding at invasive sites, bleeding requiring transfusion, bleeding associated with moderate or severe hemodynamic instability, fatal bleeding, CNS bleeding. Results of duration of overall and complete response are reported per Kaplan-Meier estimates.

Time frame:
Achievement of overall or complete response until loss of response (up to 52 weeks)
Reported as:
Median · Weeks
Duration of Overall Response (OR) and Complete Response (CR)
WeeksEltrombopag + DexamethasoneDexamethasone
Median duration of overall response8.3 (0.3 to NA)3.6 (1.1 to NA)
Median duration of complete response9.7 (1.3 to NA)1.3 (0.9 to 6.1)
SecondaryChange From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Questionnaire

The Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) instrument is a 13-item validated tool used to measure an individual's level of fatigue during usual daily activities over the past 7 days. Items are scored on a 0-4 response scale (4=not at all to 0=very much) where the total possible score ranges from 0-52 (all items are summed up to create the total score); A score of less than 30 indicates severe fatigue. The higher scores represent better HRQoL.

Time frame:
Baseline (Week 1), Week 2, 3, 5, 13, 27 and 53
Reported as:
Median · scores on a scale
Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Questionnaire
scores on a scaleEltrombopag + DexamethasoneDexamethasone
Change from Baseline (BL) to Week 2-4.2 ± 9.6-4.5 ± 6.9
Change from BL to Week1.0 ± 4.4-2.9 ± 5.1
Change from BL to Week 51.2 ± 5.0-5.1 ± 6.9
Change from BL to Week 130.3 ± 8.30.3 ± 2.8
Change from BL to Week 27-3.6 ± 11.0-3.1 ± 7.7
Change from BL to Week 532.7 ± 5.6-3.4 ± 5.4
SecondaryChange From Baseline in Short Form 36 Health Survey (SF-36v2) Questionnaire (Physical (PS), Mental Score (MS) and Alternative Scoring (PS-QM))

SF36 questionnaire is a tool to measure health-related QoL. SF36 questionnaires (physical and mental score) were answered throughout the study and is a validated instrument with 36 questions to measure general physical and mental health status via assessment of 8 domains-Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role Emotional, and Mental Health-over the past 4 weeks. The SF36 is scored using norm-based scoring procedures and scores ranging from 0-100; higher values indicate less impairment, a higher QoL. In addition to this SAP-planned scoring score, an alternative scoring for both the physical SF36 score and the mental SF36 were performed by QualityMetric (QM) Incorporated, an IQVIA business.

Time frame:
Baseline (Week 1), Week 2, 3, 5, 13, 27 and 53
Reported as:
Mean · scores on a scale
Change From Baseline in Short Form 36 Health Survey (SF-36v2) Questionnaire (Physical (PS), Mental Score (MS) and Alternative Scoring (PS-QM))
scores on a scaleEltrombopag + DexamethasoneDexamethasone
Change from Baseline (CBL) to Wk 2: Physical Score (PS)1.9 ± 4.6-3.3 ± 6.6
CBL to Week 3: PS2.5 ± 5.8-1.4 ± 8.8
CBL to Week 5: PS1.5 ± 6.2-2.7 ± 10.5
CBL to Week 13: PS3.5 ± 9.90.3 ± 8.0
CBL to Week 27: PS2.6 ± 14.7-0.9 ± 10.8
CBL to Week 53: PS8.1 ± 11.80.3 ± 10.0
CBL to Week 2: Mental Score (MS)-0.8 ± 6.1-1.2 ± 7.6
CBL to Week 3: MS-2.0 ± 11.0-1.6 ± 9.7
CBL to Week 5: MS0.1 ± 7.3-1.7 ± 11.5
CBL to Week 13: MS3.3 ± 7.54.1 ± 7.4
CBL to Week 27: MS-1.4 ± 4.9-2.7 ± 7.4
CBL to Week 53: MS2.1 ± 8.80.6 ± 5.7
CBL to Week 2: PS-QM2.0 ± 4.1-3.3 ± 6.0
CBL to Week 3: PS-QM3.4 ± 6.4-1.4 ± 7.8
CBL to Week 5: PS-QM2.4 ± 6.0-2.7 ± 8.5
CBL to Week 1: PS-QM4.1 ± 8.50.3 ± 7.6
CBL to Week 27: PS-QM3.6 ± 12.4-1.0 ± 9.7
CBL to Week 53: PS-QM6.2 ± 10.70.2 ± 9.4
SecondaryIncidence and Severity of Bleeding Events

Incidence and severity of bleeding assessed by the modified World Health Organization (WHO) Bleeding Scale; Bleeding is graded based on a 1-4 scale (1=minor bleeding to 4=severe bleeding). Incidence of bleeding: participants had at least one bleeding event. Severity of bleeding: bleeding event is from grade 2 and higher

Time frame:
Baseline up to 52 weeks
Reported as:
Count of participants · Participants
Incidence and Severity of Bleeding Events
ParticipantsEltrombopag + DexamethasoneDexamethasone
Incidence of Bleeding events1012
Incidence of Bleeding events with severity: ≥ grade 262
Incidence of Bleeding events with severity: ≥ grade 321

Adverse events

Collected over Adverse events (AEs) are collected from the first dose of study treatment until end of study treatment plus 30 days post treatment for each patient. AEs reported in this record are from first dose of study treatment until 30 days after end of treatment for each patient, approx. 3 years.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Eltrombopag + Dexamethasone0/12 (0%)5/12 (41.7%)11/12 (91.7%)
Dexamethasone1/13 (7.7%)5/13 (38.5%)13/13 (100%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventEltrombopag + DexamethasoneDexamethasone
Immune thrombocytopeniaBlood and lymphatic system disorders2/120/13
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/122/13
Aplastic anaemiaBlood and lymphatic system disorders1/120/13
Iron deficiency anaemiaBlood and lymphatic system disorders1/120/13
Oesophageal stenosisGastrointestinal disorders1/120/13
Herpes zosterInfections and infestations1/120/13
PneumoniaInfections and infestations1/120/13
B-cell lymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/120/13
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/120/13
Renal colicRenal and urinary disorders1/120/13
Most frequent other events
Showing 10 of 105
Most frequent other events
EventEltrombopag + DexamethasoneDexamethasone
PyrexiaGeneral disorders1/124/13
COVID-19Infections and infestations3/124/13
HeadacheNervous system disorders2/124/13
Abdominal painGastrointestinal disorders3/120/13
ConstipationGastrointestinal disorders3/120/13
DiarrhoeaGastrointestinal disorders3/123/13
FatigueGeneral disorders2/123/13
RashSkin and subcutaneous tissue disorders1/123/13
NauseaGastrointestinal disorders2/121/13
NasopharyngitisInfections and infestations2/121/13

Baseline characteristics

The Full Analysis Set (FAS) consists of all patients to whom study treatment has been assigned by randomization.

Age, Continuous
Age, Continuous(Years)Eltrombopag + DexamethasoneDexamethasoneTotal
Mean60.6 ± 14.545.3 ± 14.353.0 ± 16.1
Sex: Female, Male
Sex: Female, Male(Participants)Eltrombopag + DexamethasoneDexamethasoneTotal
Female6612
Male7714
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Eltrombopag + DexamethasoneDexamethasoneTotal
Caucasian121224
Other112
08

Study locations

10 sites
  • Novartis Investigative Site
    Aschaffenburg, Bayern 63739, Germany
  • Novartis Investigative Site
    Aachen, 52074, Germany
  • Novartis Investigative Site
    Chemnitz, 09113, Germany
  • Novartis Investigative Site
    Donauwoerth, 86609, Germany
  • Novartis Investigative Site
    Dortmund, 44263, Germany
  • Novartis Investigative Site
    Dresden, 01307, Germany
  • Novartis Investigative Site
    Frankfurt, 60590, Germany
  • Novartis Investigative Site
    Jena, 07740, Germany
  • Novartis Investigative Site
    Kiel, 24116, Germany
  • Novartis Investigative Site
    Kronach, 96317, Germany
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

Data sharing details ↗ · www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2020 to primary completion in Sep 2023, 35 months.

Results were first posted in Mar 2025, 1 year 5 months after primary completion.

Of 66 phase 2 interventional studies under Purpura, Thrombocytopenic, Idiopathic, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 41. This study's 35 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 12, 2020
First posted
Apr 15, 2020
StartActual
Oct 9, 2020
Primary completionActual
Sep 22, 2023
CompletionActual
Sep 22, 2023
Results first posted
Mar 17, 2025
Last update
May 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04346654
Responsible party
Sponsor
First posted
Apr 15, 2020
Start date
Oct 9, 2020
Primary completion
Sep 22, 2023
Completion
Sep 22, 2023
Results posted
Mar 17, 2025
Last update
May 16, 2025

Study contacts

Novartis Pharmaacueticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eltrombopag

Start the discussion